BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20877461)

  • 1. Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A.
    Chang JW; Hsu HS; Ni HJ; Chuang CT; Hsiung CH; Huang TH; Wang YC
    PLoS One; 2010 Sep; 5(9):e12847. PubMed ID: 20877461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
    Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
    Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
    Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
    Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation.
    Montenegro MF; Sáez-Ayala M; Piñero-Madrona A; Cabezas-Herrera J; Rodríguez-López JN
    PLoS One; 2012; 7(12):e52231. PubMed ID: 23251702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias.
    Lai HC; Lin YW; Chang CC; Wang HC; Chu TW; Yu MH; Chu TY
    Gynecol Oncol; 2007 Mar; 104(3):629-35. PubMed ID: 17097722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
    Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation influences the CTCF-modulated transcription of RASSF1A in lung cancer cells.
    Xie B; Peng F; He F; Cheng Y; Cheng J; Zhou Z; Mao W
    Cell Biol Int; 2022 Nov; 46(11):1900-1914. PubMed ID: 35989484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence.
    Marsit CJ; Kim DH; Liu M; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
    Int J Cancer; 2005 Mar; 114(2):219-23. PubMed ID: 15540210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
    Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
    Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma.
    Liu XQ; Chen HK; Zhang XS; Pan ZG; Li A; Feng QS; Long QX; Wang XZ; Zeng YX
    Int J Cancer; 2003 Aug; 106(1):60-5. PubMed ID: 12794757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma.
    Chow LS; Lo KW; Kwong J; To KF; Tsang KS; Lam CW; Dammann R; Huang DP
    Int J Cancer; 2004 May; 109(6):839-47. PubMed ID: 15027117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
    Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.
    Lorente A; Mueller W; Urdangarín E; Lázcoz P; Lass U; von Deimling A; Castresana JS
    Brain Pathol; 2009 Apr; 19(2):279-92. PubMed ID: 18616639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CTCF protein in regulating FMR1 locus transcription.
    Lanni S; Goracci M; Borrelli L; Mancano G; Chiurazzi P; Moscato U; Ferrè F; Helmer-Citterich M; Tabolacci E; Neri G
    PLoS Genet; 2013; 9(7):e1003601. PubMed ID: 23874213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTCF prevents the epigenetic drift of EBV latency promoter Qp.
    Tempera I; Wiedmer A; Dheekollu J; Lieberman PM
    PLoS Pathog; 2010 Aug; 6(8):e1001048. PubMed ID: 20730088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.